US-based medical device maker St Jude Medical has secured approval from the US Food and Drug Administration for its MediGuide enabled ablation catheters, designed to treat irregular heartbeats.
The company also announced the first use of MediGuide enabled ablation catheters, which widen the utility scope of the MediGuide system, a platform that enables clinicians to reduce the duration of radiation exposure as well as boost accuracy of ablation catheters procedures.
With the help of 3-D magnetic tracking, the MediGuide enabled ablation catheters can be visualised and using Safire duo and cool path duo the irrigated tip can be navigated in real-time on pre-recorded fluoroscopy with MediGuide Technology.
Using catheters, lesions can be created during cardiac ablation procedures to treat atrial flutter, a heart rhythm disorder where the upper chambers of the heart beat too fast and are not in sync with the lower chambers.
Due to a high-performance tip with uni-directional or bi-directional deflection, the ablation catheters can be directed in two different ways for better reach.
Besides, the catheters feature 12 irrigation ports for cooling tissue during procedures.
St Jude Medical cardiovascular and ablation technologies division president, Frank J Callaghan, noted that the MediGuide technology is an example of the firm’s commitment to providing solutions for expensive and epidemic diseases that can have a direct impact on both physicians and patients.
Utah Valley Regional Medical Center’s cardiac electrophysiology department director Dr. Chun Hwang performed the first procedure with the new ablation catheter.